Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OrniFlu
- Development stage
- Unknown
- Lead developer
- Microgen
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
OrniFlu is an inactivated subunit influenza vaccine developed by Microgen Russia. It is formulated with hemagglutinin (HA) and neuraminidase (NA) surface proteins derived from the avian influenza virus strain A/turkey/Turkey/1/05 (H5N1) and is adsorbed onto an aluminum hydroxide adjuvant. The vaccine is designed to provide active immunity against H5N1 avian influenza. It has been evaluated in clinical trials, notably at Mahidol University in Thailand, to study its immunogenicity and the priming effects of live attenuated influenza vaccines (LAIV) on the immune response to subsequent inactivated vaccine doses. The vaccine typically contains 15 mcg of hemagglutinin and 0.5 mg of aluminum hydroxide per dose.
- Brand names
- OrniFlu
- Other names
- H5N1 inactivated vaccineH-5N1 inactivated vaccineH 5N1 inactivated vaccineinactivated H5N1 influenza vaccine
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on OrniFlu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OrniFlu.